Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Marimed (MRMD) Gross Margin (2016 - 2025)

Marimed (MRMD) has disclosed Gross Margin for 15 consecutive years, with 39.91% as the latest value for Q3 2025.

  • On a quarterly basis, Gross Margin fell 143.0% to 39.91% in Q3 2025 year-over-year; TTM through Sep 2025 was 38.23%, a 452.0% decrease, with the full-year FY2024 number at 39.8%, down 456.0% from a year prior.
  • Gross Margin was 39.91% for Q3 2025 at Marimed, down from 40.47% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 59.58% in Q2 2021 to a low of 32.59% in Q4 2024.
  • A 5-year average of 45.59% and a median of 44.52% in 2023 define the central range for Gross Margin.
  • Biggest YoY gain for Gross Margin was 76bps in 2022; the steepest drop was -1410bps in 2022.
  • Marimed's Gross Margin stood at 49.9% in 2021, then dropped by -12bps to 44.13% in 2022, then grew by 1bps to 44.52% in 2023, then dropped by -27bps to 32.59% in 2024, then rose by 22bps to 39.91% in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Gross Margin are 39.91% (Q3 2025), 40.47% (Q2 2025), and 39.88% (Q1 2025).